Zuberi Faisal Faiyaz, Haroon M Amir, Haseeb Abdul, Khuhawar Shafi Muhammad
Dr. Faisal Faiyaz Zuberi, M.B.B.S., F.C.P.S (Med)., F.C.P.S (Pulm), FCCP. Associate Professor Pulmonology, Head of Chest Unit-II, Dow University of Health Sciences, Karachi, Pakistan.
Dr. M. Amir Haroon, M.B.B.S., D.T.C.D., M.D. Pulmonologist and Consultant Physician, Sindh Government Hospital Liaquatabad, Karachi, Pakistan.
Pak J Med Sci. 2020 Nov-Dec;36(7):1517-1522. doi: 10.12669/pjms.36.7.2657.
Our objective was to evaluate the effect of Montelukast on the symptoms of asthma and allergic rhinitis (AR), assess its effect on the individual quality of life (QoL), and estimate the proportion of participants having adverse effects.
This prospective, open-label study conducted at Dow University of Health Sciences, Ankle Saria Hospital and Sindh Government Hospital Liaquatabad, Karachi, from August 2018 to September 2019, included patients aged >18 years with a clinical diagnosis of Asthma, AR, or both. Patients were given a 10 mg Montelukast tablet each day and then called for follow-up in the fourth week, where the questions related to the improvement in the symptoms of asthma or AR were asked. Patients were also asked about the improvement in QoL and any adverse effects.
A total of 694 patients were registered of which 138(19.8%) had AR, 294(42.4%) had asthma, while 273(39.3%) had both. Mean age was 41.1±14.63 years and 352 (50.7%) were male and 342(49.3%) were females. On a follow-up visit, there was a sufficient improvement in 351 asthmatics (63.9%), and 288 patients with AR (70.1%) overall, strong or marked improvement in the day (n=342,62.3%) and night time (n=331,60.3%) asthma symptoms. Overall improvements in QoL were very good or good in 419 patients. Montelukast was well-tolerated here with adverse effects (like abdominal discomfort, fever, fatigue, headache, rash, and upper respiratory tract symptoms) seen in 125 patients (18.01%).
Montelukast was very effective in improving the symptoms and QoL of the individuals suffering from asthma and/or AR.
我们的目的是评估孟鲁司特对哮喘和变应性鼻炎（AR）症状的影响，评估其对个体生活质量（QoL）的影响，并估计出现不良反应的参与者比例。
这项前瞻性、开放标签研究于2018年8月至2019年9月在卡拉奇的道健康科学大学、安可·萨里亚医院和信德省政府利亚夸塔巴德医院进行，纳入年龄大于18岁、临床诊断为哮喘、AR或两者皆有的患者。患者每天服用10毫克孟鲁司特片，然后在第四周进行随访，询问与哮喘或AR症状改善相关的问题。还询问了患者生活质量的改善情况以及任何不良反应。
共登记694例患者，其中138例（19.8%）患有AR，294例（42.4%）患有哮喘，273例（39.3%）两者皆有。平均年龄为41.1±14.63岁，男性352例（50.7%），女性342例（49.3%）。随访时，351例哮喘患者（63.9%）总体有足够改善，288例AR患者（70.1%）总体有足够改善，白天（n = 3４2，62.3%）和夜间（n = 331，60.3%）哮喘症状有显著或明显改善。419例患者生活质量总体改善非常好或良好。孟鲁司特在此耐受性良好，125例患者（18.01%）出现不良反应（如腹部不适、发热、疲劳、头痛、皮疹和上呼吸道症状）。
孟鲁司特对改善哮喘和/或AR患者的症状及生活质量非常有效。
